Jupiter Wellness (JUPW) Golden Cross Chart, the 50 DMA Just Crossed Above the 200
Good day everyone,
Jupiter Wellness, Inc. (NASDAQ: JUPW is engaged in research and development with a product pipeline addressing hair loss, eczema, burns, and sexual wellness.
Current price $1.32/share (as of 10:40 a.m. EDT 11-15-22)
After closing the Tuesday session at $1.29, JUPW shares traded as high as $1.34/share early in the Wednesday session. There were 168K shares traded by the 10:40 AM. We expect the swing in JUPW’s value to continue.
My biggest takeaway from the Q3 earnings report this week was JUPW saying it will spin off their SRM division to their shareholders as its own separate NASDAQ traded company by year-end. Jupiter Wellness will remain the largest shareholder and the proposed transaction could happen before the end of the year.
Why would the company spin off the source of over 90% of its current revenue? I can think of two reasons:
JUPW will develop biopharma-based revenues beginning in Q4 2022. Their recent accretive acquisition of Applied biology came with a history of $8M in annual revenues. Add to that, revenues from the lucrative licensing deals recently negotiated with Taisho, in Japan, Cosmofix Technovation Pvt Ltd and Sanpellegrino Cosmetics in India. Both of those deals could start generating a steady stream of 2023 revenues.
Secondly, changing SRM into an independent NASDAQ listed company may help that company grow as funding for expansion could be more readily obtainable. That would be a benefit for both JUPW and its current shareholders.
Stay tuned. We have another potential runner coming this week.
The Traders News Group
original report below
Jupiter Wellness (JUPW) is Making Moves to Enhance Shareholder Value with a Recently Announced Dividend, Spin-Off and Lucrative Biopharma Deals
Revenues are growing and costs are down.
Good day everyone,
Jupiter Wellness, Inc. (NASDAQ: JUPW) is engaged in research and development with a product pipeline addressing hair loss, eczema, burns, and sexual wellness.
Current price $1.29/share (as of market close 11-15-22)
JUPW is a very interesting biopharma company and I expect 2023 may be their breakout year. The company generates revenue through the sales of OTC and consumer products, contract research agreements, licensing royalties, and through their subsidiary SRM. All these revenue streams are hitting stride in H2 this year and the company will record revenues in 2022 with the prospects for a breakout in 2023 looking good.
When I put all the pieces together and get a good grasp on the direction this company appears to be headed, it looks exciting. They’ve made some savvy accretive acquisitions, put together some lucrative licensing deals for their products, and aligned with world class distributors. I don’t think I’m the only one excited because JUPW shares are experiencing a nice swing right now that I think may just be starting.
FYE 2020 $1.0M
FYE 2021 $2.8M
FYE 2022 $7.0M (my estimate based on 9 mos. revenue of $5.2M)
Q3 22 revenues were $1,569,925 compared to $687,928 for the same period in 2021.
Operating expenses were $2,196,502, compared to $3,609,223 for the same period in 2021.
Net losses were $2,232,426 compared to $4,808,430 for the same period in 2021.
Director, Dr. Skender Fani, filed a Form 4 reporting the purchase of 122,000 shares on October 25.
JUPW signed an exclusive licensing agreement with Rejoy, Inc., to develop prescription products for the treatment of nipple neuropathies and associated sexual problems in women that have been treated for breast cancer.
Brian John, CEO of Jupiter Wellness, said, ” With combined sales orders shipped or received in the Third Quarter of over $5 million just coming off a record revenue in the Second Quarter, we are well on our way toward profitability by mid-2023.”
John continued, “We plan to file to spin off our SRM division to our shareholders as its own separate NASDAQ traded company by year-end. Jupiter Wellness will remain the largest shareholder while enabling us to access additional capital to grow the SRM business at a faster pace.”
The spin-off of SRM could be a real boon to shareholders operating as a separate company. With revenues already in place ($5.2M in the first 9 months of 2022), gross profit of $1M, and a backlog of $3.6M, SRM has the attributes to stand alone as a successful company. SRM has nothing to do with biopharma. JUPW acquired the company in November 2020, and it supplies the amusement park industry with exclusive products throughout the worldwide theme park industry.
JUPW clearly has their focus on developing a thriving biopharma-based business as the company’s most recent acquisitions, license agreements and partnerships have been in that sector and their focus is beginning to pay off. Read below to see everything the company has done in the biopharma sector.
Began their Contract Research Organization business – The JUPW CRO business was established through the acquisition of Ascent Clinical Research (ACR) assets in Q2 2022 and the accretive acquisition of Applied Biology (AB) assets in Q3 2022. In 2021 AB recognized revenues of approximately $8Mwith $4M in EBITDA. For the ACR assets, the company has paid $1.3M to date and will receive 5% royalties on sales derived from the assets.
The JUPW biopharma product pipeline:
Photocil – Topical treatment for psoriasis and vitiligo (on the market)
It is anticipated that Photocil will be available online in the United States in Q4 2022 as an FDA-approved OTC product. See the recent events news about the huge India distribution deal below.
NoStingz – Topical protection from jellyfish, sea lice, and UVA/UVB rays (on the market)
NoStingz has been available online through Amazon and Walmart as well as in select stores starting in April-June 2022 with sales ramping up month-over-month.
Minoxidil Booster – Topical treatment designed to improve Minoxidil efficacy (on the market)
Licensed to Taisho, in Japan with a $300k up-front payment and 3% royalties on net sales. Also licensed to India-based Cosmofix Technovation Pvt Ltd and Sanpellegrino Cosmetics with a $50k up-front payment 10% royalties on net sales.
JW-100 – Topical treatment of eczema (in development)
Currently in a comparison study against EUCRISA by Pfizer with results expected in Q1 2023. See the latest news about the potential for this product below.
RJ-101 – Topical treatment for female sexual wellness (in development)
See the just announced licensing news with Rejoy, Inc. that I mentioned supplies the amusement park industry with exclusive products throughout the worldwide theme park industry.
JW-300 – Topical treatment of first-degree burns and sun exposure (in development)
A pre-revenue product and currently being evaluated.
JW-400 – Topical treatment of cold sores (in development)
A pre-revenue product. Clinical studies are needed before assessing a pathway to market.
Recent events at JUPW:
JUPW announced last week that it has re-opened enrollment in a clinical trial aimed at evaluating the superiority of JW-100, a novel cannabidiol topical cream, in a head-to-head study against EUCRISA, an FDA Approved topical treatment for eczema developed by Pfizer.
The continuation of the study is big news for the company because if JW-100 were to be found as effective or better than EUCRISA it could lead to a share of hundreds of millions in sales that Pfizer gets from their product. JUPW expects study completion in Q1 2023.
Earlier this month JUPW announced that its Photocil product (branded as PhotoFirst in India) has been approved by the CDSCO for sale in India. Photocil is a topical product that filters UV rays from the sun to allow only the therapeutic UV spectrum to penetrate the skin. It is used for the treatment of psoriasis and vitiligo. The commercial launch is expected to begin in Q1 2023. Distribution will be through Sanpellegrino Cosmetics Pvt Ltd & Cosmofix Technovation Pvt Ltd with whom JUPW signed a licensing agreement covering 31 countries.
JUPW has announced plans to transfer and spin off 40% of its wholly owned subsidiary, Caring Brands Inc, a developer of cann-a-bidiol based therapeutics and wellness products, by way of a dividend. Jupiter will maintain 60%. The dividend will be in the form of digital securities and will be transferred to shareholders with a record date to occur in late November.
FYE is December 31st – MRQ is September 30, 2022
Revenues (ttm) $5.95M
Outstanding shares 21.6M
Shares in float 15.8M
Cash (mrq) $3.5M
Insider ownership 43%
Market cap $26M
As the chart below indicates, JUPW shares have broken through all their SMA averages and are moving to new highs.
We will have an updated report soon,
The Traders News Group
Do we disclose any information to outside parties?
We do not sell your information to anyone.
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails.
The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice.
All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The owners and operators of this website have been compensated twenty thousand dollars cash via bank wire for this weeks distributed opinions on jupw. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement.
TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.
We use technologies like cookies to store and/or access device information. We do this to improve browsing experience and to show personalized ads. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.